Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Bortezomib (Primary) ; Cytarabine; Dexamethasone; Rituximab
- Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms R-HAD
- 24 Jul 2017 This trial has been suspended in Germany as per European Clinical Trials Database.
- 06 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Dec 2018.
- 06 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2018.